Which has higher valuation and earnings, ANL or FTLF?

FitLife Brands has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 75.92 -$35.53M N/A N/A FitLife Brands $81.46M 1.33 $6.33M $0.60 19.17

Do analysts rate FTLF or PRTC?

FitLife Brands presently has a consensus price target of $21.50, indicating a potential upside of 86.96%. Given FitLife Brands' stronger consensus rating and higher probable upside, equities research analysts clearly believe FitLife Brands is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, FTLF or PRTC?

FitLife Brands has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FitLife Brands $81.46M 1.33 $6.33M $0.60 19.17 PureTech Health $4.66M 91.01 -$109.74M N/A N/A

FitLife Brands (FTLF) Competitors

$11.50 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$11.28 -0.22 (-1.87%)

As of 07/2/2026 04:10 PM Eastern

Compare

FTLF vs. ANL, SLN, AUTL, PRTC, and IPSC

Should you buy FitLife Brands stock or one of its competitors? MarketBeat compares FitLife Brands with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FitLife Brands include Adlai Nortye (ANL), Silence Therapeutics (SLN), Autolus Therapeutics (AUTL), PureTech Health (PRTC), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry.

How does FitLife Brands compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Adlai Nortye's average media sentiment score of 0.00 equaled FitLife Brands'average media sentiment score.

Company	Overall Sentiment
Adlai Nortye	Neutral
FitLife Brands	Neutral

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 61.7% of FitLife Brands shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Adlai Nortye currently has a consensus price target of $24.25, suggesting a potential upside of 155.53%. FitLife Brands has a consensus price target of $21.50, suggesting a potential upside of 86.96%. Given Adlai Nortye's stronger consensus rating and higher probable upside, research analysts plainly believe Adlai Nortye is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

FitLife Brands has a net margin of 6.64% compared to Adlai Nortye's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Adlai Nortye's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
FitLife Brands	6.64%	18.31%	8.21%

Adlai Nortye has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

FitLife Brands has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	75.92	-$35.53M	N/A	N/A
FitLife Brands	$81.46M	1.33	$6.33M	$0.60	19.17

Summary

Adlai Nortye and FitLife Brands tied by winning 6 of the 12 factors compared between the two stocks.

How does FitLife Brands compare to Silence Therapeutics?

FitLife Brands (NASDAQ:FTLF) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

2.3% of FitLife Brands shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 61.7% of FitLife Brands shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Silence Therapeutics had 1 more articles in the media than FitLife Brands. MarketBeat recorded 1 mentions for Silence Therapeutics and 0 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.00 beat Silence Therapeutics' score of -0.72 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Overall Sentiment
FitLife Brands	Neutral
Silence Therapeutics	Negative

FitLife Brands has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.33	$6.33M	$0.60	19.17
Silence Therapeutics	$560K	876.47	-$88.61M	-$1.59	N/A

FitLife Brands currently has a consensus price target of $21.50, indicating a potential upside of 86.96%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 429.36%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

FitLife Brands has a net margin of 6.64% compared to Silence Therapeutics' net margin of -8,943.86%. FitLife Brands' return on equity of 18.31% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

FitLife Brands has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Summary

FitLife Brands beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does FitLife Brands compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Autolus Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 453.80%. FitLife Brands has a consensus target price of $21.50, suggesting a potential upside of 86.96%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

FitLife Brands has a net margin of 6.64% compared to Autolus Therapeutics' net margin of -311.98%. FitLife Brands' return on equity of 18.31% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
FitLife Brands	6.64%	18.31%	8.21%

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 61.7% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

FitLife Brands has lower revenue, but higher earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	4.54	-$287.53M	-$1.09	N/A
FitLife Brands	$81.46M	1.33	$6.33M	$0.60	19.17

Autolus Therapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

In the previous week, Autolus Therapeutics had 1 more articles in the media than FitLife Brands. MarketBeat recorded 1 mentions for Autolus Therapeutics and 0 mentions for FitLife Brands. Autolus Therapeutics' average media sentiment score of 0.00 equaled FitLife Brands'average media sentiment score.

Company	Overall Sentiment
Autolus Therapeutics	Neutral
FitLife Brands	Neutral

Summary

Autolus Therapeutics beats FitLife Brands on 9 of the 16 factors compared between the two stocks.

How does FitLife Brands compare to PureTech Health?

FitLife Brands (NASDAQ:FTLF) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, PureTech Health had 2 more articles in the media than FitLife Brands. MarketBeat recorded 2 mentions for PureTech Health and 0 mentions for FitLife Brands. PureTech Health's average media sentiment score of 0.30 beat FitLife Brands' score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
FitLife Brands	Neutral
PureTech Health	Neutral

FitLife Brands presently has a consensus price target of $21.50, indicating a potential upside of 86.96%. Given FitLife Brands' stronger consensus rating and higher probable upside, equities research analysts clearly believe FitLife Brands is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

FitLife Brands has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

FitLife Brands has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.33	$6.33M	$0.60	19.17
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 61.7% of FitLife Brands shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

FitLife Brands has a net margin of 6.64% compared to PureTech Health's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
PureTech Health	N/A	N/A	N/A

Summary

FitLife Brands beats PureTech Health on 10 of the 14 factors compared between the two stocks.

How does FitLife Brands compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Century Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

FitLife Brands has a net margin of 6.64% compared to Century Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
FitLife Brands	6.64%	18.31%	8.21%

FitLife Brands has lower revenue, but higher earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	4.01	-$9.58M	-$1.14	N/A
FitLife Brands	$81.46M	1.33	$6.33M	$0.60	19.17

Century Therapeutics currently has a consensus price target of $4.75, indicating a potential upside of 95.47%. FitLife Brands has a consensus price target of $21.50, indicating a potential upside of 86.96%. Given Century Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Century Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 61.7% of FitLife Brands shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Century Therapeutics' average media sentiment score of 0.00 equaled FitLife Brands'average media sentiment score.

Company	Overall Sentiment
Century Therapeutics	Neutral
FitLife Brands	Neutral

Summary

Century Therapeutics and FitLife Brands tied by winning 7 of the 14 factors compared between the two stocks.

Get FitLife Brands News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTLF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTLF vs. The Competition

Export

Metric	FitLife Brands	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$108M	$8.69B	$7.16B	$12.48B
Dividend Yield	N/A	2.45%	2.66%	6.52%
P/E Ratio	19.04	16.55	28.02	24.70
Price / Sales	1.33	6.06	540.55	99.42
Price / Cash	9.86	18.11	49.26	57.09
Price / Book	2.47	3.53	10.96	6.46
Net Income	$6.33M	$226.25M	$3.57B	$337.01M
7 Day Performance	3.79%	1.50%	2.12%	1.69%
1 Month Performance	16.51%	-0.23%	5.25%	3.81%
1 Year Performance	-18.44%	-0.49%	33.29%	23.90%

FitLife Brands Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTLF FitLife Brands	4.5314 of 5 stars	$11.50 flat	$21.50 +87.0%	-18.4%	$108M	$81.46M	19.04	20	Gap Down
ANL Adlai Nortye	1.536 of 5 stars	$10.99 +3.7%	$24.25 +120.7%	+506.0%	$439.60M	$5M	N/A	127
SLN Silence Therapeutics	2.4522 of 5 stars	$9.16 +26.0%	$55.00 +500.4%	+87.5%	$432.67M	$839K	N/A	100	Gap Up High Trading Volume
AUTL Autolus Therapeutics	1.9911 of 5 stars	$1.61 -3.3%	$8.75 +445.2%	-33.3%	$427.19M	$75.39M	N/A	330
PRTC PureTech Health	0.1257 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTLF) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FitLife Brands (FTLF) Competitors

FTLF vs. ANL, SLN, AUTL, PRTC, and IPSC

How does FitLife Brands compare to Adlai Nortye?

Summary

How does FitLife Brands compare to Silence Therapeutics?

Summary

How does FitLife Brands compare to Autolus Therapeutics?

Summary

How does FitLife Brands compare to PureTech Health?

Summary

How does FitLife Brands compare to Century Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF vs. The Competition

FitLife Brands Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FitLife Brands (FTLF) Competitors

FTLF vs. ANL, SLN, AUTL, PRTC, and IPSC

How does FitLife Brands compare to Adlai Nortye?

Does the media favor ANL or FTLF?

Do institutionals & insiders hold more shares of ANL or FTLF?

Do analysts prefer ANL or FTLF?

Is ANL or FTLF more profitable?

Which has more volatility & risk, ANL or FTLF?

Which has higher valuation and earnings, ANL or FTLF?

Summary

How does FitLife Brands compare to Silence Therapeutics?

Do insiders and institutionals believe in FTLF or SLN?

Does the media prefer FTLF or SLN?

Which has higher earnings and valuation, FTLF or SLN?

Do analysts rate FTLF or SLN?

Is FTLF or SLN more profitable?

Which has more volatility and risk, FTLF or SLN?

Summary

How does FitLife Brands compare to Autolus Therapeutics?

Do analysts recommend AUTL or FTLF?

Is AUTL or FTLF more profitable?

Do insiders & institutionals hold more shares of AUTL or FTLF?

Which has stronger earnings & valuation, AUTL or FTLF?

Which has more volatility and risk, AUTL or FTLF?

Does the media favor AUTL or FTLF?

Summary

How does FitLife Brands compare to PureTech Health?

Does the media refer more to FTLF or PRTC?

Do analysts rate FTLF or PRTC?

Which has more risk and volatility, FTLF or PRTC?

Which has higher valuation and earnings, FTLF or PRTC?

Do insiders and institutionals hold more shares of FTLF or PRTC?

Is FTLF or PRTC more profitable?

Summary

How does FitLife Brands compare to Century Therapeutics?

Which has more volatility & risk, IPSC or FTLF?

Is IPSC or FTLF more profitable?

Which has higher earnings and valuation, IPSC or FTLF?

Do analysts rate IPSC or FTLF?

Do insiders & institutionals believe in IPSC or FTLF?

Does the media favor IPSC or FTLF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF vs. The Competition

FitLife Brands Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools